Purpose: To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH). Scope: In this open-label, noncontrolled, observational surveillance study, 3684 men with BPH received 4-8 mg of controlled-release doxazosin gastrointestinal therapeutic system (GITS) for 6 months; 3283 (89.1%) patients completed the trial. Changes in urinary symptoms and quality of life were assessed using the International Prostate Symptom Score (IPSS). Blood pressure and adverse events were assessed. Conclusion: After 6 months' treatment with doxazosin GITS resulted in significant improvements in IPSS. BP was reduced only in hypertensive patients. Doxazosin, GITS was well tolerated.
Introduction
The amount of healthcare resources expended in the treatment of benign prostatic hyperplasia (BPH) in most developed countries is considerable because of its high incidence and prevalence. Chicharro et al 1 estimated the prevalence of urinary symptoms due to BPH (International Prostate Symptom Score (IPSS)X8) to be 24.9% in men aged over 40 y in the Andalusian Autonomous Region of Spain. The prevalence is 36.6% in Japan according to a study by Tsukamoto 2 and 14.2% in France in a study by Sagnier. 3 Autopsies have revealed histological evidence of BPH in 90% of men older than 90 y of age. 4 As early as 1978, studies by Caine and Shapiro 5, 6 demonstrated that a-blocking drugs such as phenoxybenzamine and prazosin reduced urethral resistance, thus facilitating bladder emptying. Doxazosin blocks a 1 -adrenergic receptors; thereby decreasing sympathetic nervous system-activated muscular tone in the bladder neck and prostatic urethra. The result is less resistance to the outflow of urine from the bladder, an improved urinary flow rate, and a reduction in lower urinary tract symptoms.
It has been estimated that the incidence of concomitant BPH and hypertension is at least one in eight in men aged 60 y or more. It has been suggested that the conditions may have a common etiology in the sympathetic nervous system. 7 Unlike many antihypertensive agents, doxazosin has a beneficial effect on serum lipids. [8] [9] [10] A controlled-release doxazosin formulation was developed in a gastrointestinal therapeutic system (GITS), which allows a more constant and gradual controlled release of the drug over a 24-h period. The doxazosin GITS formulation has an enhanced pharmacokinetic profile and drug delivery rate compared with the standard formulation, eliminating the need for slow titration to achieve a therapeutic dose. 11 This study of doxazosin GITS, a noncontrolled, openlabel, observational drug surveillance study in patients with BPH, was designed to analyze the reduction in urinary symptoms, evaluate the difference in quality of life, and determine potential adverse events (AEs) in a large group of men. Additionally, the study observed the effect of doxazosin GITS on blood pressure (BP) in a stratified analysis of normotensive and hypertensive patients with BPH.
Methods
Patients with BPH who were distributed across all geographic areas of Spain were recruited into the study between September 2000 and February 2001. Those eligible for the study were male outpatients 440 y old with moderate to severe BPH symptoms 47 points on the IPSS and a diagnosis of BPH by rectal examination and/or ultrasound. Patients were excluded if they had hepatic impairment, gastrointestinal or esophageal obstruction, drug reaction to a-adrenergic blockers or quinazolines, prostate-specific antigen (PSA) levels 44 ng/ml, imminent prostatectomy, indwelling bladder catheter, recurrent hematuria, orthostatic hypotension, syncope, low systolic BP (SBPo95 mmHg) and/or diastolic BP (DBPo60 mmHg), stroke, acute myocardial infarction within the previous 3 months, or treatment with other a-blockers. This study was conducted in accordance with Good Clinical Practice guidelines.
On the first visit, patients were initiated at 4 mg daily of doxazosin GITS for 2 months. On the second visit after 2 months, the dosage was increased to 8 mg/day if necessary. The optimally adjusted dose was then maintained until the third visit at 6 months, which was the end of the treatment period. Effectiveness was evaluated using the IPSS. The final question of the IPSS scale was used to measure quality of life related to urinary symptoms. For the purposes of this trial, a score of o8 on the IPSS was considered optimal BPH symptom control.
To study BP changes, patients were divided into two subgroups: hypertensive with BP 4140/90 mmHg (64%) or normotensive with BP o140/90 mmHg (36%). The number and percentage of patients who achieved a mean BP reduction to o140/90 mmHg was determined. Metabolic parameters, including lipid profiles, fasting glucose, and changes in PSA values, were analyzed. Additionally, effectiveness was calculated according to treatment compliance, hypertension, and age groups.
Safety was evaluated by measuring the number and percentage of patients experiencing any AEs or serious AEs, the most frequent AEs, and the number withdrawing owing to AEs.
The results of the study are reported for the intent-totreat (ITT) population, which included all recruited patients who were prescribed treatment with doxazosin on the baseline visit and who had at least one posttreatment IPSS assessment in addition to the baseline assessment. Of the 3684 patients recruited in the study, 3463 (94%) belonged to this data set. Results for the per protocol (PP) population are reported because of the slight variation of the population definition. The PP group included all patients who completed the 6-month trial of the study medication with good (80-120%) or fair (50-79%) compliance (n ¼ 3111; 84%). AEs are reported for all patients enrolled in the study who took at least 1 dose of doxazosin (safety population, n ¼ 3684; 100%).
An analysis of covariance using the general linear model procedure was performed with all the demographic and baseline variables as independent variables and the decrease in the IPSS score as the dependent variable. The correlation matrices of all quantitative and ordinal variables were obtained using SAS s . Effectiveness results were reported by number of patients and by mean7standard deviation (s.d.). The safety evaluation included data on AEs and the subgroup of normotensive patients. Statistical significance was determined at P ¼ 0.05.
Results

Patient populations
A total of 374 individual investigators participated and 3684 patients were recruited; 3283 (89.1%) patients completed the study. Reasons for withdrawal are reported in Table 1 . Efficacy results are reported for the ITT population (n ¼ 3463). There were 3111 patients in the PP population who were also analyzed for completeness; however, for the purposes of this trial, these data are reported only as they compare with the analysis in the ITT population. The safety population comprised all enrolled patients (n ¼ 3684), all of whom were treated with at least one dose of doxazosin GITS. The mean age of patients (7s.d.) in the safety population was 65.178.3 y.
Efficacy
Urinary symptoms In the ITT population, therapy with doxazosin GITS for 6 months significantly reduced the total IPSS by 7.6875.14 points (Po0.001 vs baseline; Figure 1 ). More than one-third (1158/3271, 35.4%) of the patients achieved optimal control of urinary symptoms with an IPSS o8 points. Analysis of the PP population yielded results similar to those of the ITT population (Po0.001 for IPSS improvement from baseline). No statistical method was used to replace missing data when IPSS was not measured; the data were considered lost. 
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A subgroup analysis stratified by baseline IPSS was performed, generating four homogenous groups with 25% of the sample in each group. The greatest reduction of prostate symptoms occurred in patients that had more severe scores on the baseline IPSS (Figure 2 ). The differences among the groups were statistically significant (Po0.001).
The analysis of dose-response showed that only 4% (n ¼ 117) of patients required an increase in dose to 8 mg; of these, 26.1% achieved control of urinary symptoms with an IPSS o8 points after 6 months.
Patients who had a mean quality-of-life score of 3.7970.86 points at baseline achieved a mean score of 1.6971.0 points (Po0.001) after 6 months of treatment, indicating a significant improvement in quality of life due to improvement in urinary symptoms. Figure 3 shows the quality-of-life improvement over the 6 months of treatment. Significant improvements were observed at 2 and 6 months (Po0.001).
Blood pressure The subgroup of hypertensive patients (n ¼ 2110, 64%) had a mean BP of 151712/8679 mmHg at baseline (Figure 4) . Analysis of the drug's effectiveness in terms of this parameter showed that BP control (o140/90 mmHg) was achieved in a significant number of patients (n ¼ 785, 40%) during the 6-month trial (Po0.001 for changes from baseline in SBP and DBP at 2 and 6 months). The mean BP reduction was À10.4/ À5.5 mmHg; this effect on BP was apparent by the second month of treatment when a significant BP reduction was observed in 32.6% of patients (Po0.001).
Hypertensive patients who required a dose increase to Controlled-release doxazosin for BPH C Hernandez et al 8 mg showed the same proportion of BP control (40%) as those who remained on 4 mg. In contrast, BP in normotensive patients (n ¼ 1193, 36%) was not significantly altered after treatment with doxazosin GITS (Figure 4 ).
Metabolic parameters and PSA Treatment for 6 months with doxazosin GITS significantly reduced serum glucose, uric acid, total cholesterol, and low-density lipoprotein (LDL) cholesterol; high-density lipoprotein (HDL) cholesterol was significantly increased. PSA was not significantly changed during the study (Table 2) .
Safety
The safety analysis was conducted in all patients. A total of 255 AEs were reported in 225 patients (6%). Of these, 19 (0.52%) were serious, including three deaths. None of the serious AEs or deaths were found to be related to the study treatment. A total of 136 patients reported AEs (3.69%) considered to be related to treatment. In all, 107 patients (2.9%) withdrew from the study owing to AEs. By groups, the most frequently reported AEs were nervous system disorders (2.44%), cardiovascular problems (2.06%), and gastrointestinal disorders (1%) ( Table 3) .
Discussion
The findings in this open-label study demonstrating that doxazosin GITS is effective and well tolerated for the treatment of symptomatic BPH are supported by the data in randomized, placebo-controlled trials. 12, 13 This study, although not comparative, showed the effectiveness of doxazosin GITS in a large number of patients with BPH. In addition, doxazosin GITS improved quality of life, with patients who were 'mostly unhappy' at the beginning of the study showing improvement to 'pleased' or 'mostly satisfied' after 6 months of treatment.
In the present study, improvement in urinary symptoms and hypertension was observed early, and effectiveness was maintained despite the long treatment period. BP was controlled in 32.6% of hypertensive patients in the second month after the start of treatment. In previous reports, a reduction in BP clearly occurred in hypertensive patients treated with doxazosin, but the hypotensive effect in persons with previously normal BP was much smaller. 14, 15 This finding was confirmed in our study. Doxazosin has been shown to be effective for BP reduction when used as part of a combination therapy regimen in hypertensive patients. 16, 17 Although a lipid evaluation was not the primary efficacy measure of this study, we found that doxazosin reduced total cholesterol and LDL and increased HDL. These results are consistent with other studies with standard doxazosin. [18] [19] [20] [21] Consistent with data from other trials, doxazosin GITS was well tolerated in this trial. Although the main objective of this study was not to evaluate sexual Controlled-release doxazosin for BPH C Hernandez et al function by means of a specific questionnaire, it is important to note that only one nonserious treatmentrelated AE associated with sexual function was reported (one case of impotence). Unlike the AEs commonly reported in trials with other BPH therapies, such as erectile dysfunction and decreased libido with the 5a-reductase inhibitor finasteride 22 and abnormal ejaculation with some a-blockers, 23, 24 doxazosin GITS for the treatment of BPH is associated with improvements in sexual function in BPH patients with concomitant sexual dysfunction. 25 These findings confirm the results of randomized controlled trials in BPH patients 13 ; however, the exclusion criteria for PSA X4 ng/ml and history of hypotension and orthostasis do favor a greater symptom improvement and reduced AE frequency than might be found in an unselected population. The lack of a control group, however, is not limiting because the data are consistent with those in similar patient populations from randomized controlled trials and open-label studies.
Conclusions
Therapy with doxazosin GITS resulted in a reduction in symptoms and improvement in quality of life in patients with BPH. BP was controlled in 32.6% of hypertensive patients in the second month after the start of treatment. The findings of this open-label study demonstrate that the controlled-release formulation of doxazosin was well tolerated and improved patients' lipid profiles. Controlled-release doxazosin for BPH C Hernandez et al
